BOSTON - TelAve -- ScionxBio, a preclinical-stage RNA therapeutics company, today announces its emergence from stealth, after completing a strategic horizontal split by Eleven Therapeutics. ScionxBio will advance a groundbreaking xRNA modality, a next-generation mRNA therapeutic, and its cardio-metabolic asset pipeline. Dr. Adi Gilboa-Geffen, Eleven's former CTO, has been appointed as ScionxBio's CEO. Dr. Yaniv Erlich, co-founder and former CEO of Eleven Therapeutics, joins ScionxBio as Co-Founder and Chairman of the Board of Directors. Shaul Ilan, co-founder of Eleven Therapeutics, joins ScionxBio as Co-Founder, COO, and Board Member.

ScionxBio is the continuation of Eleven Therapeutics' xRNA mission: an asset-focused company with a validated platform, a defined pipeline, and single focus - developing long-acting xRNA therapeutics for cardio-metabolic disease.

More on TelAve News

• UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
• Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
• June Employment Report Reveals Hidden Weakness Beneath Lower Unemployment
• Phinge Home Of Netverse, Is Actively Investigating The "Model Context Protocol" (MCP) For Infringement Of Its IP From Its June, 2021 Priority Dates
• Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules

ScionxBio's xRNA platform is built on the company's proprietary TERÅ® technology, which uses combinatorial chemistry and deep-learning architectures to engineer RNA molecules with significantly enhanced structural stability and resistance to enzymatic degradation. ScionxBio is applying xRNA to cardio-metabolic disease, where long-acting, consistent protein expression has direct implications for patient burden, treatment durability, and the immunogenic risk associated with repeat administration.

"I have spent my career building things that did not exist, always alongside great teams and great scientists. The years I spent at Eleven Therapeutics, leading the research together with Yaniv and the team, were no different. We asked whether we could engineer RNA to last. Today, we have a proven modality, validated data, and a pipeline ready to move. The science phase is behind us. What comes next is building medicines.

"Patients with chronic metabolic disease face a lifetime of frequent dosing - and with it, accumulated immunogenic risk, side effects, and exposure peaks and troughs. Long-acting xRNA addresses all of that. Sustained expression. Significantly reduced immunogenic burden. A different class of medicine."

More on TelAve News

• Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
• Make America French Again Launches National Campaign
• RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
• 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
• Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area

- Dr. Adi Gilboa-Geffen, PhD, CEO and Board Member

ABOUT SCIONXBIO

ScionxBio, formerly Eleven Therapeutics, is a Cambridge-based preclinical biotechnology company developing long-acting, programmable xRNA therapeutics for cardio-metabolic disease. The company's TERÅ® platform applies combinatorial chemistry and deep learning to engineer RNA molecules with exceptional stability and sustained protein expression, enabling infrequent dosing and consistent therapeutic effect. ScionxBio emerged from stealth, having operated independently since January 2026 following the completion of a horizontal split by Eleven Therapeutics, with a focused mission to develop next-generation xRNA therapeutics for cardio-metabolic disease.

Dr. Adi Gilboa-Geffen, CEO - ScionxBio
press@scionxbio.com | http://www.scionxbio.com

This press release contains forward-looking statements. Actual results may differ materially. ScionxBio undertakes no obligation to update such statements.

Written to endure.